Literature DB >> 25546754

Dosing and individualized treatment - patient-centric treatment: changing practice guidelines.

H S Patwa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546754      PMCID： PMC4285483          DOI： 10.1111/cei.12503

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  18 in total

1.  Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy.

Authors:  M Vermeulen; F G van der Meché; J D Speelman; A Weber; H F Busch
Journal:  J Neurol Sci       Date:  1985-10       Impact factor: 3.181

2.  Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy.

Authors:  Lotte Vlam; Elisabeth A Cats; Eline Willemse; Hessel Franssen; Jelena Medic; Sanne Piepers; Jan H Veldink; Leonard H van den Berg; W-Ludo van der Pol
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-12-11       Impact factor: 10.154

3.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  A Fateh-Moghadam; M Wick; U Besinger; R G Geursen
Journal:  Lancet       Date:  1984-04-14       Impact factor: 79.321

4.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

5.  Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.

Authors:  Philippe Gajdos; Christine Tranchant; Bernard Clair; Francis Bolgert; Bruno Eymard; Tanya Stojkovic; Shahram Attarian; Sylvie Chevret
Journal:  Arch Neurol       Date:  2005-11

6.  Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.

Authors:  Norito Kokubun; Tsubasa Sada; Nobuhiro Yuki; Momoka Okabe; Koichi Hirata
Journal:  Eur Neurol       Date:  2013-06-19       Impact factor: 1.710

7.  Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days.

Authors:  J C Raphael; S Chevret; M Harboun; M C Jars-Guincestre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-08       Impact factor: 10.154

Review 8.  Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  H S Patwa; V Chaudhry; H Katzberg; A D Rae-Grant; Y T So
Journal:  Neurology       Date:  2012-03-27       Impact factor: 9.910

9.  Comparison of American and European practices in the management of patients with primary immunodeficiencies.

Authors:  H S Hernandez-Trujillo; H Chapel; V Lo Re; L D Notarangelo; B Gathmann; B Grimbacher; J M Boyle; V P Hernandez-Trujillo; C Scalchunes; M L Boyle; J S Orange
Journal:  Clin Exp Immunol       Date:  2012-07       Impact factor: 4.330

10.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321
View more
  2 in total

1.  Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.

Authors:  Willem Jan R Fokkink; Sander J van Tilburg; Brenda C M de Winter; Sebastiaan D T Sassen; Pieter A van Doorn; Birgit C P Koch; Bart C Jacobs
Journal:  Clin Pharmacokinet       Date:  2022-07-04       Impact factor: 5.577

2.  Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  K Kuitwaard; E Brusse; B C Jacobs; A F J E Vrancken; F Eftimov; N C Notermans; A J van der Kooi; W-J R Fokkink; D Nieboer; H F Lingsma; I S J Merkies; P A van Doorn
Journal:  Eur J Neurol       Date:  2020-10-01       Impact factor: 6.089
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.